JP2015521592A5 - - Google Patents

Download PDF

Info

Publication number
JP2015521592A5
JP2015521592A5 JP2015516648A JP2015516648A JP2015521592A5 JP 2015521592 A5 JP2015521592 A5 JP 2015521592A5 JP 2015516648 A JP2015516648 A JP 2015516648A JP 2015516648 A JP2015516648 A JP 2015516648A JP 2015521592 A5 JP2015521592 A5 JP 2015521592A5
Authority
JP
Japan
Prior art keywords
polypeptide
item
isolated polypeptide
seq
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015516648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015521592A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/062553 external-priority patent/WO2013189901A1/en
Publication of JP2015521592A publication Critical patent/JP2015521592A/ja
Publication of JP2015521592A5 publication Critical patent/JP2015521592A5/ja
Pending legal-status Critical Current

Links

JP2015516648A 2012-06-18 2013-06-17 安定化されたgp120 Pending JP2015521592A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261661050P 2012-06-18 2012-06-18
US61/661,050 2012-06-18
PCT/EP2013/062553 WO2013189901A1 (en) 2012-06-18 2013-06-17 Stabilized gp120

Publications (2)

Publication Number Publication Date
JP2015521592A JP2015521592A (ja) 2015-07-30
JP2015521592A5 true JP2015521592A5 (cg-RX-API-DMAC10.html) 2016-08-04

Family

ID=48628698

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015516648A Pending JP2015521592A (ja) 2012-06-18 2013-06-17 安定化されたgp120

Country Status (14)

Country Link
US (1) US20150183835A1 (cg-RX-API-DMAC10.html)
EP (1) EP2861249A1 (cg-RX-API-DMAC10.html)
JP (1) JP2015521592A (cg-RX-API-DMAC10.html)
KR (1) KR20150023735A (cg-RX-API-DMAC10.html)
CN (1) CN104619338A (cg-RX-API-DMAC10.html)
AU (1) AU2013279456A1 (cg-RX-API-DMAC10.html)
CA (1) CA2876762A1 (cg-RX-API-DMAC10.html)
IL (1) IL235898A0 (cg-RX-API-DMAC10.html)
IN (1) IN2014KN02740A (cg-RX-API-DMAC10.html)
MX (1) MX2014014682A (cg-RX-API-DMAC10.html)
RU (1) RU2015101081A (cg-RX-API-DMAC10.html)
SG (1) SG11201407995RA (cg-RX-API-DMAC10.html)
WO (1) WO2013189901A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201408840B (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10400015B2 (en) 2014-09-04 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
US10010605B2 (en) * 2014-09-23 2018-07-03 Merial, Inc. FMDV recombinant vaccines and uses thereof
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3426291A1 (en) 2016-03-09 2019-01-16 The U.S.A. as represented by the Secretary, Department of Health and Human Services Recombinant hiv-1 envelope proteins and their use
MX2019004681A (es) 2016-10-21 2019-10-07 Altor Bioscience Corp Moleculas basadas en il-15 multimericas.
EP3697440A1 (en) 2017-10-16 2020-08-26 The United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant hiv-1 envelope proteins and their use
CN109851664A (zh) * 2017-11-30 2019-06-07 清华大学 一种基于抗体反向表位设计的蛋白质及其在制备抗艾滋病病毒疫苗中的应用
MX2020013621A (es) 2018-06-19 2021-03-25 Nantcell Inc Composiciones y metodos de tratamiento de vih.
WO2021249013A1 (en) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Vaccine compositions, methods, and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786488B1 (fr) * 1998-11-27 2003-04-25 Orstom Mutants de la gp120 et leurs applications biologiques
WO2001000648A1 (en) * 1999-06-25 2001-01-04 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
JP2010536885A (ja) * 2007-08-24 2010-12-02 ノバルティス アーゲー V3ループに改変を有するhivenvタンパク質
US9175070B2 (en) * 2009-09-25 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use

Similar Documents

Publication Publication Date Title
RU2015101081A (ru) Стабилизированный gp120
US12162907B2 (en) Subunit vaccine for treatment or prevention of a respiratory tract infection
JP2015214545A5 (cg-RX-API-DMAC10.html)
WO2009002418A3 (en) T-cell peptide epitopes from carcinoembryonic antigen, immunogenic analogs, and uses thereof
JP2015500827A5 (cg-RX-API-DMAC10.html)
JP2012530761A5 (cg-RX-API-DMAC10.html)
JP2010522540A5 (cg-RX-API-DMAC10.html)
WO2007106476A3 (en) Compositions and methods for enhancing the immunogenicity of antigens
JP2018510215A5 (cg-RX-API-DMAC10.html)
JP2009520758A5 (cg-RX-API-DMAC10.html)
JP2012530504A5 (cg-RX-API-DMAC10.html)
JP2018512856A5 (cg-RX-API-DMAC10.html)
JP2016156828A5 (cg-RX-API-DMAC10.html)
WO2009015842A3 (en) Novel immunogenic epitopes for immunotherapy
JP2012500001A5 (cg-RX-API-DMAC10.html)
IL274130B2 (en) Novel scaffolded hiv-1 vaccine immunogens
JP2016520534A5 (cg-RX-API-DMAC10.html)
US20240358812A1 (en) Human metapneumovirus combination vaccine
JP2016504993A5 (cg-RX-API-DMAC10.html)
RU2018116601A (ru) Иммунногенный слитый белок
UA107180C2 (uk) Туберкульозний білок rv1753c, композиція, що його містить, та застосування
JP2012102105A5 (cg-RX-API-DMAC10.html)
JP2013520487A5 (cg-RX-API-DMAC10.html)
JP2014502961A5 (cg-RX-API-DMAC10.html)
RU2015140603A (ru) Вакцины на основе нуклеопротеина вируса гриппа